2m 2m 2m 2m 2m 2m 2m
TEVAPHARMIND SP ADR (TEVA)
NYSE
$33.09+$0.88 (+2.75%)
Price as of Jun 23, 2026 7:48 PM EDT- $37.5BMarket Cap
- 89.75%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
TEVAPHARMIND SP ADR (TEVA)
$33.09+$0.88 (+2.75%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 17.3B +4.32% | 16.5B +4.40% | 15.8B +6.17% | 14.9B -6.00% | |
Cost of Revenue | 8.3B -1.90% | 8.5B +3.43% | 8.2B +3.12% | 8.0B -4.01% | |
Gross Profit | 8.9B +10.84% | 8.1B +5.48% | 7.6B +9.64% | 7.0B -8.18% | |
Sales and Marketing Expense | 2.7B +5.71% | 2.5B +8.78% | 2.3B +3.13% | 2.3B -6.75% | |
Research and Development Expense | -1.0B +1.50% | -998.0M +4.72% | -953.0M +13.72% | -838.0M -13.34% | |
Depreciation and Amortization Expense | 1.0B -5.38% | 1.1B -8.15% | 1.2B -11.85% | 1.3B -1.65% | |
Total Operating Expenses | 8.3B -1.90% | 8.5B +3.43% | 8.2B +3.12% | 8.0B -4.01% | |
Operating Profit | 2.2B +811.88% | -303.0M -169.98% | 433.0M +120.63% | -2.1B -222.32% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -916.0M -8.58% | -1.0B -2.62% | -1.0B +10.65% | -930.0M +4.38% | |
Interest Income and Expense and Net | -916.0M -8.58% | -1.0B -2.62% | -1.0B +10.65% | -930.0M +4.38% | |
Total Nonoperating Income and Expense | -934.0M -4.79% | -981.0M -7.19% | -1.1B +9.42% | -966.0M -8.70% | |
Income before Taxes | 1.2B +195.25% | -1.3B +105.77% | -624.0M -79.64% | -3.1B -565.81% | |
Income Taxes | -180.0M -126.63% | 676.0M +9,757.14% | -7.0M -98.90% | -638.0M -402.37% | |
Extraordinary Items | N/A N/A | N/A N/A | 1.1B -55.95% | 2.4B +319.01% | |
Net Income | 1.4B +186.03% | -1.6B +193.20% | -559.0M -76.24% | -2.4B -664.27% | |
Net Income from Continuing Operations Applicable to Common | 1.4B +186.03% | -1.6B +193.20% | -559.0M -76.24% | -2.4B -664.27% | |
Basic EPS and Net Income | 1.23 +184.83% | -1.45 +190.00% | -0.50 -76.42% | -2.12 -657.89% | |
Diluted EPS and Net Income | 1.21 +183.45% | -1.45 +190.00% | -0.50 -76.42% | -2.12 -657.89% | |
Basic Weighted Average Shares | 1.1B +1.24% | 1.1B +1.07% | 1.1B +0.81% | 1.1B +0.73% | |
Diluted Weighted Average Shares | 1.2B +2.83% | 1.1B +1.07% | 1.1B +0.81% | 1.1B +0.27% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 3.6B +7.76% | 3.3B +2.29% | 3.2B +15.17% | 2.8B +29.38% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 3.6B +7.76% | 3.3B +2.29% | 3.2B +15.17% | 2.8B +29.38% | |
Total Current Assets | 13.9B +11.11% | 12.6B +0.54% | 12.5B +3.60% | 12.1B -4.15% | |
Accumulated Depreciation | 4.7B +7.21% | 4.4B -21.77% | 5.6B +2.16% | 5.5B +5.29% | |
Property and Plant and Equipment and Net | 4.1B -10.94% | 4.6B -20.33% | 5.8B +0.19% | 5.7B -4.06% | |
Total Long-Term Assets | 405.0M -12.34% | 462.0M -1.70% | 470.0M +6.58% | 441.0M -14.37% | |
Total Assets | 40.7B +3.62% | 39.3B -9.55% | 43.5B -1.20% | 44.0B -7.68% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 1.8B +2.19% | 1.8B +6.52% | 1.7B -20.72% | 2.1B +47.90% | |
Total Current Liabilities | 13.5B +5.16% | 12.8B +4.48% | 12.2B +6.78% | 11.5B +4.01% | |
Total Long-Term Debt | 15.0B -6.35% | 16.0B -11.89% | 18.2B -4.93% | 19.1B -11.63% | |
Total Long-Term Liabilities | 19.4B -6.87% | 20.8B -9.94% | 23.1B -3.10% | 23.8B -6.10% | |
Total Liabilities | 32.8B -2.30% | 33.6B -4.94% | 35.4B +0.11% | 35.3B -3.04% | |
Retained Earnings | -13.8B -9.30% | -15.2B +12.11% | -13.5B +5.06% | -12.9B +22.35% | |
Total Stockholders Equity | 7.9B +47.22% | 5.4B -28.42% | 7.5B -4.95% | 7.9B -23.17% | |
Total Shares Outstanding | 1.3B +1.37% | 1.2B +1.06% | 1.2B +0.82% | 1.2B +0.66% | |
Cash Flow | |||||
Cash from Operating Activities | 1.6B +32.24% | 1.2B -8.85% | 1.4B -13.96% | 1.6B +99.25% | |
Capital Expenditures | 501.0M +0.60% | 498.0M -5.32% | 526.0M -4.01% | 548.0M -2.49% | |
Cash from Investing Activities | 737.0M -6.94% | 792.0M -18.18% | 968.0M +47.56% | 656.0M -56.93% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -2.2B +20.10% | -1.8B -6.38% | -1.9B +28.65% | -1.5B -31.54% | |
Financials Ratio | |||||
Gross Margin | 51.79% +6.27% | 48.74% +1.00% | 48.25% +3.28% | 46.72% -2.31% | |
Operating Margin | 12.50% +782.42% | -1.83% -167.02% | 2.73% +119.43% | -14.06% -230.13% | |
Return on Assets | 3.52% +188.96% | -3.96% +209.78% | -1.28% -75.11% | -5.13% -705.08% | |
Return on Equity | 21.23% +183.41% | -25.45% +250.66% | -7.26% -71.97% | -25.89% -730.36% | |
Revenue Growth | 4.32% -2.02% | 4.40% -28.62% | 6.17% +202.81% | -6.00% +28.02% | |
Current Ratio | 1.04 +5.66% | 0.98 -3.78% | 1.02 -2.98% | 1.05 -7.85% | |
Cash Ratio | 0.26 +2.48% | 0.26 -2.09% | 0.26 +7.86% | 0.24 +24.40% | |
Debt-to-Equity Ratio | 2.12 -35.80% | 3.31 +25.26% | 2.64 -1.63% | 2.69 +19.81% | |
Debt-to-Assets Ratio | 0.41 -8.80% | 0.45 -0.88% | 0.46 -5.35% | 0.48 -0.29% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow